Synergistic killing of NDM-producing MDR Klebsiella pneumoniae by two 'old' antibiotics-polymyxin B and chloramphenicol

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2589-2597

  Rahim, Nusaibah Abdul ^a   Cheah, Soon Ee ^a   Johnson, Matthew D ^a   Yu, Heidi ^a   Sidjabat, Hanna E ^b   Boyce, John ^a   Butler, Mark S ^c   Cooper, Matthew A ^c   Fu, Jing ^a   Paterson, David L ^b,d   Nation, Roger L ^a   Bergen, Phillip J ^a   Velkov, Tony ^a   Li, Jian ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

K. pneumoniae; New Delhi metallo lactamase; Synergy

Indexed keywords

CHLORAMPHENICOL; METALLO BETA LACTAMASE; MULTIDRUG RESISTANCE PROTEIN; NEW DELHI METALLO BETA LACTAMASE; POLYMYXIN B; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL; BACTERIAL GENE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG POTENTIATION; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; SCANNING ELECTRON MICROSCOPY; DRUG EFFECTS; ENZYMOLOGY; MICROBIAL VIABILITY; MULTIDRUG RESISTANCE; PHYSIOLOGY; SECRETION (PROCESS);

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHLORAMPHENICOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; KLEBSIELLA PNEUMONIAE; MICROBIAL VIABILITY; POLYMYXIN B;

EID: 84946759595     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv135     Document Type: Article

References (47)

1. NDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53: 5046-54.
2. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10: 597-602.
3. NDM-1 gene in Gram-negative rods. FEMS Microbiol Lett 2011; 324: 111-6.
4. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
5. ECDC. Updated Risk Assessment on the Spread of NDM and its Variants Within Europe. Stockholm: ECDC, 2011. http://ecdc.europa.eu/en/publications/Publications/1111_TER_Risk-assessment-NDM.pdf.
6. CDC. Antibiotic Resistance Threats in the United States, 2013. http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf.
7. Livermore DM, Warner M, Mushtaq S et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-9.
8. Velkov T, Roberts KD, Nation RL et al. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol 2013; 8: 711-24.
9. Bergen PJ, Li J, Rayner CR et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006; 50: 1953-8.
10. Li J, Nation RL, Milne RW et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int J Antimicrob Agents 2005; 25: 11-25.
11. Arpin C, Noury P, Boraud D et al. NDM-1-producing Klebsiella pneumoniae resistant to colistin in a French community patient without history of foreign travel. Antimicrob Agents Chemother 2012; 56: 3432-4.
12. Garonzik SM, Li J, Thamlikitkul V et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55: 3284-94.
13. Rahal JJ. Novel antibiotic combinations against infections with almost completely resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2: S95-9.
14. Laferriere CI, Marks MI. Chloramphenicol: properties and clinical use. Pediatr Infect Dis 1982; 1: 257-64.
15. Kawakami M, Nagai Y, Shimizu S et al. Anti-microbial effect of combinations of colistin methanesulfonate and chloramphenicol. I. In vitro effect. J Antibiot (Tokyo) 1971; 24: 884-91.
16. Brock TD. Chloramphenicol. Bacteriol Rev 1961; 25: 32-48.
17. Sidjabat H, Nimmo GR, Walsh TR et al. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi metallo-β-lactamase. Clin Infect Dis 2011; 52: 481-4.
18. NDM-1-carrying plasmid in Escherichia coli ST131 and Klebsiella pneumoniae ST11 and ST15 isolates in Thailand. J Antimicrob Chemother 2014; 69: 3161-3.
19. Day KM, Salman M, Kazi B et al. Prevalence of NDM-1 carbapenemase in patients with diarrhoea in Pakistan and evaluation of two chromogenic culture media. J Appl Microbiol 2013; 114: 1810-6.
20. Magiorakos AP, Srinivasan A, Carey RB et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 268-81.
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-third Informational Supplement M100-S23. CLSI, Wayne, PA, USA, 2013.
22. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 4.0. 2014. http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/Breakpoint_table_v_4.0.pdf.
23. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J Antimicrob Chemother 2011; 66: 2070-4.
24. Rogers BA, Sidjabat HE, Silvey A et al. Treatment options for New Delhi metallo-β-lactamase-harboring enterobacteriaceae. Microb Drug Resist 2013; 19: 100-3.
25. Hudson CM, Bent ZW, Meagher RJ et al. Resistance determinants and mobile genetic elements of an NDM-1-encoding Klebsiella pneumoniae strain. PLoS One 2014; 9: e99209.
26. Bergen PJ, Forrest A, Bulitta JB et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother 2011; 55: 5134-42.
27. Zavascki AP, Goldani LZ, Cao G et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 2008; 47: 1298-304.
28. Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet 1984; 9: 222-38.
29. Koup JR, Lau AH, Brodsky B et al. Chloramphenicol pharmacokinetics in hospitalized patients. Antimicrob Agents Chemother 1979; 15: 651-7.
30. Cheah SE, Li J, Nation RL et al. A novel rate-area-shape modeling approach to quantify bacterial killing and regrowth for in vitro static time-kill studies. Antimicrob Agents Chemother 2015; 59: 381-8.
31. Ketthireddy S et al. In vivo pharmacodynamics of colistin against Pseudomonas aeruginosa in thighs of neutropenic mice. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, 2007. Abstract A-4, p. 1. American Society for Microbiology, Washington, DC, USA.
32. Poudyal A, Howden BP, Bell JM et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2008; 62: 1311-8.
33. Deris ZZ, Yu HH, Davis K et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2012; 56: 5103-12.
34. Bergen PJ, Tsuji BT, Bulitta JB et al. Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 2011; 55: 5685-95.
35. Tam VH, Schilling AN, Vo G et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49: 3624-30.
36. Choi MJ, Ko KS. Mutant prevention concentrations of colistin for Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae clinical isolates. J Antimicrob Chemother 2014; 69: 275-7.
37. Sandri AM, Landersdorfer CB, Jacob J et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 2013; 57: 524-31.
38. Tangden T, Hickman RA, Forsberg P et al. Evaluation of double-and triple-antibiotic combinations for VIM-and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments. Antimicrob Agents Chemother 2014; 58: 1757-62.
39. Civljak R, Giannella M, Di Bella S et al. Could chloramphenicol be used against ESKAPE pathogens? A review of in vitro data in the literature from the 21st century. Expert Rev Anti Infect Ther 2014; 12: 249-64.
40. Wareham DW, Wilson P. Chloramphenicol in the 21st century. Hosp Med 2002; 63: 157-61.
41. Burke JT, Wargin WA, Sherertz RJ et al. Pharmacokinetics of intravenous chloramphenicol sodium succinate in adult patients with normal renal and hepatic function. J Pharmacokinet Biopharm 1982; 10: 601-14.
42. Velkov T, Thompson PE, Nation RL et al. Structure-activity relationships of polymyxin antibiotics. J Med Chem 2010; 53: 1898-916.
43. Schindler PR, Teuber M. Action of polymyxin B on bacterial membranes: morphological changes in the cytoplasm and in the outer membrane of Salmonella typhimurium and Escherichia coli B. Antimicrob Agents Chemother 1975; 8: 95-104.
44. Koike M, Iida K, Matsuo T. Electron microscopic studies on mode of action of polymyxin. J Bacteriol 1969; 97: 448-52.
45. Lounatmaa K, Makela PH, Sarvas M. Effect of polymyxin on the ultrastructure of the outer membrane of wild-type and polymyxin-resistant strain of Salmonella. J Bacteriol 1976; 127: 1400-7.
46. Waisbren SJ, Hurley DJ, Waisbren BA. Morphological expressions of antibiotic synergism against Pseudomonas aeruginosa as observed by scanning electron microscopy. Antimicrob Agents Chemother 1980; 18: 969-75.
47. Bulitta JBLJ, Poudyal A, Yu HH et al. Quantifying synergy of colistin combinations against MDR gram negatives by mechanism-based models. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, 2009. Abstract A1-573, p. 41. American Society for Microbiology, Washington, DC, USA.